Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 415 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
415 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic solid tumors harboring a KRAS alteration (mutation or amplification) who have progressed on, are ineligible for, or declined standard-of-care therapy (Arm D additionally requires PD-L1 TPS ≥50%; excludes untreated CNS metastases and ILD/pneumonitis). Participants receive the first-in-human agent BMS-986523 (target/mechanism not publicly described) as monotherapy or combined with pembrolizumab (anti–PD-1), cetuximab (anti-EGFR), or gemcitabine plus nab-paclitaxel.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Adults with locally advanced/metastatic measurable solid tumors harboring any KRAS mutation or wild-type KRAS amplification (ECOG 0–1) after 1–4 prior systemic regimens are treated with IV PT0511 monotherapy in dose-escalation/expansion cohorts; a colorectal cancer expansion cohort receives PT0511 plus cetuximab (anti-EGFR). PT0511 is an investigational KRAS-altered tumor–directed agent, but its specific molecular mechanism/allele selectivity is not publicly specified.
ClinicalTrials.gov ID: NCT07300150
TrialFetch AI summary: Adults with unresectable locally advanced/metastatic EGFR-mutant NSCLC (ECOG 0–1) with progression after prior first- or second-line osimertinib (alone or with chemotherapy), excluding those with other actionable drivers or known EGFR osimertinib-resistance mutations. Treatment is continued osimertinib plus escalating-dose oral NXP900 (eCF506), a selective SRC-family kinase inhibitor (high potency vs YES1; also SRC) designed to lock kinases in an inactive conformation to address resistance biology.
ClinicalTrials.gov ID: NCT07315113
TrialFetch AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05519293
TrialFetch AI summary: The trial investigates the use of AG01, an anti-progranulin/GP88 monoclonal antibody, in patients with relapsed or refractory advanced solid tumors, including triple negative breast cancer, hormone-resistant breast cancer, non-small cell lung cancer, and mesothelioma, who have no remaining effective treatment options. AG01 is administered biweekly to evaluate its safety, tolerability, and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05627960
TrialFetch AI summary: This trial is focused on patients with metastatic or locally advanced solid tumors, specifically colorectal cancer and non-small cell lung cancer, investigating the safety and efficacy of EU101, an agonistic monoclonal antibody targeting the 4-1BB receptor to enhance immune response.
ClinicalTrials.gov ID: NCT04903873
TrialFetch AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.
ClinicalTrials.gov ID: NCT05227326
TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.
ClinicalTrials.gov ID: NCT04787042
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors harboring RET gene abnormalities, including both NSCLC and other solid tumors, regardless of prior RET inhibitor exposure. Patients receive TAS0953/HM06 (vepafestinib), an oral selective RET tyrosine kinase inhibitor active against resistance mutations and designed for enhanced CNS penetration.
ClinicalTrials.gov ID: NCT04683250
TrialFetch AI summary: Eligible patients are adults with advanced NSCLC, head and neck squamous cell carcinoma, cervical cancer, or uterine carcinoma, whose tumors express the NEO-201 antigen and who have progressed after standard therapies. Treatment consists of NEO-201 (a monoclonal antibody targeting tumor-associated O-glycans and CEACAM5/1 pathway) in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT03476681